CHINA PHARMA HOLDINGS INC (CPHI)
US16941T3023 - Common Stock
We assign a fundamental rating of 1 out of 10 to CPHI. CPHI was compared to 194 industry peers in the Pharmaceuticals industry. CPHI has a bad profitability rating. Also its financial health evaluation is rather negative. CPHI is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CPHI has reported negative net income.
In the past year CPHI had a positive cash flow from operations.
In the past 5 years CPHI always reported negative net income.
CPHI had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
CPHI has a Return On Assets (-30.88%) which is in line with its industry peers.
CPHI's Return On Equity of -59.45% is in line compared to the rest of the industry. CPHI outperforms 51.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.88% | ||
| ROE | -59.45% | ||
| ROIC | N/A |
ROA(3y)-18.68%
ROA(5y)-32.54%
ROE(3y)-63.46%
ROE(5y)-90.06%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CPHI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CPHI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CPHI has been increased compared to 1 year ago.
CPHI has more shares outstanding than it did 5 years ago.
CPHI has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -4.39, we must say that CPHI is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CPHI (-4.39) is worse than 63.54% of its industry peers.
CPHI has a debt to FCF ratio of 9.89. This is a negative value and a sign of low solvency as CPHI would need 9.89 years to pay back of all of its debts.
CPHI has a better Debt to FCF ratio (9.89) than 82.81% of its industry peers.
A Debt/Equity ratio of 0.38 indicates that CPHI is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.38, CPHI is not doing good in the industry: 61.98% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.38 | ||
| Debt/FCF | 9.89 | ||
| Altman-Z | -4.39 |
ROIC/WACCN/A
WACC5.88%
2.3 Liquidity
A Current Ratio of 0.84 indicates that CPHI may have some problems paying its short term obligations.
CPHI has a Current ratio of 0.84. This is amonst the worse of the industry: CPHI underperforms 90.63% of its industry peers.
A Quick Ratio of 0.24 indicates that CPHI may have some problems paying its short term obligations.
The Quick ratio of CPHI (0.24) is worse than 96.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.84 | ||
| Quick Ratio | 0.24 |
3. Growth
3.1 Past
CPHI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.76%, which is quite impressive.
Looking at the last year, CPHI shows a very negative growth in Revenue. The Revenue has decreased by -21.36% in the last year.
The Revenue for CPHI have been decreasing by -10.68% on average. This is quite bad
EPS 1Y (TTM)73.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.27%
Revenue 1Y (TTM)-21.36%
Revenue growth 3Y-13.59%
Revenue growth 5Y-10.68%
Sales Q2Q%-15.76%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
CPHI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, CPHI is valued cheaply inside the industry as 89.06% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.51 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CPHI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CHINA PHARMA HOLDINGS INC
NYSEARCA:CPHI (11/22/2024, 8:04:03 PM)
After market: 0.2017 +0.01 (+4.78%)0.1925
-0.01 (-3.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.30M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.88% | ||
| ROE | -59.45% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.38 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.84 | ||
| Quick Ratio | 0.24 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)73.76%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-21.36%
Revenue growth 3Y-13.59%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y